Balinska M A
Institut National de Prevention et d'Education pour la Sante, Direction des Affaires Scientifiques, Coordinateur de Programme-Maladies Infectieuses, Immeuble Etoile-Pleyel, 93203 Saint-Denis Cedex, France.
Vaccine. 2004 Mar 29;22(11-12):1335-42. doi: 10.1016/j.vaccine.2004.01.039.
Successful immunization programmes have reduced the burden of a number of infectious diseases on a global scale. Yet, as the fear of sequelae of vaccine-preventable diseases diminishes in the public, the focus of interest has shifted towards true and alleged "side effects". Maintaining confidence in the necessity, tolerability and safety of immunizations is of paramount importance today. This requires, amongst other prerequisites, precise definitions of "adverse events following immunization". In Europe, a collaborative effort named EUSAFEVAC in concert with the globally active "Brighton Collaboration" has been initiated. Volunteers from academic institutions, vaccine licensing authorities, public health institutes, governmental organizations, safety units within the vaccine manufacturing industry as well as practising physicians are working together to achieve this goal.
成功的免疫规划在全球范围内减轻了多种传染病的负担。然而，随着公众对疫苗可预防疾病后遗症的担忧减少，人们的关注焦点已转向真正的以及所谓的“副作用”。如今，维持对免疫接种的必要性、耐受性和安全性的信心至关重要。这除了其他先决条件外，还需要对“免疫接种后不良事件”进行精确界定。在欧洲，已启动了一项名为EUSAFEVAC的合作项目，并与全球活跃的“布莱顿协作组织”协同开展工作。来自学术机构、疫苗许可当局、公共卫生机构、政府组织、疫苗生产行业的安全部门以及执业医师的志愿者们正在共同努力以实现这一目标。
